PCN85 - Cost-Minimization Analysis of Lipegfilgrastim in Prophylaxis Of Febrile Neutropenia in Cancer Patients

Abstract

To conduct cost-minimization analysis of lipegfilgrastim compared with pegfilgrastim, filgrastim, lenograstim in prophylaxis of febrile neutropenia (FN) in cancer patients in Russia for 1-year period. A cost-minimization model was developed in Excel 2013 to simulate the costs for 1-year period. The total number of patients with FN in Russia according to the statistics equals 110556. The following costs were taken into account: costs for the treatment course with granulocyte colony-stimulating factor drugs (including ones for administration of the drugs), costs for the treatment of a FN event, expenses for management of adverse events associated with administration of granulocyte colony-stimulating factor drugs. The average tender prices for the study drugs were used as the source of data on prices for G-CSFs. The number of administrations and bottles per administration were calculated in accordance with Prescribing Information for the drugs. According to the Program of state guarantees for provision of free medical care the costs of each FN event is 119,808 rubles. Adverse events management was calculated according to the data on the incidence of adverse events from the Prescribing information documents and tariffs of Federal Compulsory Medical Insurance Fund. According to the cost-minimization analysis, the least costly was prophylaxis with lipegfilgrastim (211484 rubles/3200 $) by the end of the 1st year per 1 patient. Costs in pegfilgrastim group resulted in 314986 rubles/4766 $, in filgrastim group (11 days of treatment) – 264620 rubles/4004 $, in lenograstim group (11 days of treatment) – 690798 rubles/10452 $. Current rate taken as for 15.06.2016 is 1$ = 66,09 RUB. The prophylaxis with lipegfilgrastim is a cost saving option compared with G-CSF registered for prophylaxis of febrile neutropenia in cancer patients in Russia for 1-year period.